CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
| 対象疾患 | Acute Lymphoblastic Leukemia |
|---|---|
| 相 | 第2相 |
| スポンサー | M.D. Anderson Cancer Center |
| ステータス | 完了 |
| 参加者数 | 90 名 |
| 介入（薬剤） | CMC-544 (Inotuzumab Ozogamycin), Rituximab |
| 開始日 | 2010年6月4日 |
| 完了日 | 2018年4月18日 |
| 結果公開日 | 2019年5月22日 |
概要
The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Number of Patients With Response
| Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2 | 3 Participants |
|---|---|
| Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2 | 25 Participants |
| Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin) | 24 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diag — National Cancer Institute (NCI)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Tr — National Cancer Institute (NCI)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibruti — National Cancer Institute (NCI)
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituxim — National Cancer Institute (NCI)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual — National Cancer Institute (NCI)
- Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute — Wake Forest University Health Sciences